Novartis’ “son of Glivec” (Tasigna) carrying on the family tradition – Novartis has reported result of Tasigna Phase III clinical trial. In the study, Tasigna (nilotinib) demonstrated greater efficacy over Glivec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase…more
Need to count calories as part of your diabetes regimen? Yep – there’s an app for that. Developed by Sanofi-Aventis with InTouch Solutions.
Worried about prostate cancer? There may be an app for that – coffee!
Quick overview of a growing trend – personalized medicine.
Territory Management. Need to train your sales reps in better territory management (and selling skills)? We have vendor/providers for that, in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
JUST FOR FUN
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Connect with Steve Woodruff